[Off-label use in psychiatry].
In psychiatry, there is an increasing use of drugs Off-Label. Especially antidepressants and antipsychotic drugs are prescribed more often outside approved indications. Main problems with Off-Label Use are drug safety, lack of reimbursement by health care providers and insufficient coordination between clinics and primary care psychiatrists. Many, especially older psychotropic drugs are approved for psychopathologic phenomena rather than on ICD-10 categories. According to current judication of the German supreme court for social issues, specific criteria for Off-Label Use have been defined. Now, in social legislation, under particular circumstances Off-Label Use is feasible. Recommendations of expert groups for psychiatry are currently lacking, but are expected in next future for Methylphenidate in treatment of adult attention-deficit-hyperactive disorder (ADHS). Especially important for all psychiatrists is to receive informed consent of the patient before initiation of a drug therapy Off-Label.
Weih
M
M
Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen. markus.weih@uk-erlangen.de
Thürauf
N
N
Bleich
S
S
Kornhuber
J
J
D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D017277:Drug Approval; D011307:Drug Prescriptions; D004363:Drug Utilization; D005858:Germany; D006778:Hospitals, Psychiatric; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D008774:Methylphenidate / Q000627:therapeutic use; D011570:Psychiatry / Q000592:standards / Q000639:trends*; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D011619:Psychotropic Drugs; D008774:Methylphenidate